Kim Van der Eecken
Overview
Explore the profile of Kim Van der Eecken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
290
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Van der Eecken K, Van der Linden M, Raman L, Creytens D, Dedeurwaerdere F, De Winne K, et al.
Virchows Arch
. 2022 Jan;
480(3):677-686.
PMID: 35034191
Copy number alterations (CNAs) have increasingly become part of the diagnostic algorithm of glial tumors. Alterations such as homozygous deletion of CDKN2A/B, 7 +/ 10 - chromosome copy number changes...
12.
Sutera P, Van der Eecken K, Kishan A, Hamid A, Grist E, Attard G, et al.
Prostate Cancer Prostatic Dis
. 2022 Jan;
25(4):713-719.
PMID: 35013522
Background: Several definitions have attempted to stratify metastatic castrate-sensitive prostate cancer (mCSPC) into low and high-volume states. However, at this time, comparison of these definitions is limited. Here we aim...
13.
Van der Eecken K, Vanwelkenhuyzen J, Deek M, Tran P, Warner E, Wyatt A, et al.
Eur Urol Oncol
. 2021 Nov;
4(6):914-923.
PMID: 34801437
Context: Multiple studies have reported on the genomic characteristics of metastatic hormone-sensitive prostate cancer (mHSPC). The impact of these findings on prognostication, treatment selection, and clinical trial design remains unclear....
14.
Jasu J, Tolonen T, Antonarakis E, Beltran H, Halabi S, Eisenberger M, et al.
Eur Urol Open Sci
. 2021 Aug;
30:47-62.
PMID: 34337548
Background: Systematic identification of data essential for outcome prediction in metastatic prostate cancer (mPC) would accelerate development of precision oncology. Objective: To identify novel phenotypes and features associated with mPC...
15.
Deek M, Van der Eecken K, Phillips R, Parikh N, Velho P, Lotan T, et al.
Eur Urol
. 2021 Jan;
80(5):632-640.
PMID: 33419682
Background: Emerging data suggest that metastasis is a spectrum of disease burden rather than a binary state, and local therapies, such as radiation, might improve outcomes in oligometastasis. However, current...
16.
de Schaetzen van Brienen L, Larmuseau M, Van der Eecken K, De Ryck F, Robbe P, Schuh A, et al.
BMC Med Genomics
. 2020 Jul;
13(1):94.
PMID: 32631411
Background: Research grade Fresh Frozen (FF) DNA material is not yet routinely collected in clinical practice. Many hospitals, however, collect and store Formalin Fixed Paraffin Embedded (FFPE) tumor samples. Consequently,...
17.
Raman L, Van der Linden M, Van der Eecken K, Vermaelen K, Demedts I, Surmont V, et al.
Genome Med
. 2020 Apr;
12(1):35.
PMID: 32317009
Background: Accurate lung cancer classification is crucial to guide therapeutic decisions. However, histological subtyping by pathologists requires tumor tissue-a necessity that is often intrinsically associated with procedural difficulties. The analysis...
18.
Lancia A, Zilli T, Achard V, Dirix P, Everaerts W, Gomez-Iturriaga A, et al.
Cancer Treat Rev
. 2019 Jan;
73:84-90.
PMID: 30684842
Oligometastatic prostate cancer represents an intermediate state between a localized tumor and widespread metastatic disease. Its specific clinical features suggest the existence of a distinct biology which still needs to...
19.
Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere P, Fonteyne V, et al.
Eur Urol
. 2019 Jan;
75(5):707-711.
PMID: 30665814
Preclinical data indicate that radiotherapy works synergistically with pembrolizumab, but the effect and toxicity of this combination may depend on radiotherapy timing. We conducted a randomized phase 1 trial combining...
20.
Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, et al.
World J Urol
. 2018 Dec;
37(12):2557-2564.
PMID: 30578441
Purpose: Patients with oligometastatic prostate cancer (PC) may benefit from metastasis-directed therapy (MDT), delaying disease progression and the start of palliative systemic treatment. However, a significant proportion of oligometastatic PC...